CJC-1295 no DAC / Ipamorelin

Tirzepatide (Tirz) — Next-Generation Dual Agonist Research Compound

One of the most advanced metabolic research compounds available. TR2 (Tirz) is a "next-generation" peptide that acts as a dual agonist, targeting two different receptors simultaneously.

Product Overview

TR2 (Tirz) is a synthetic, 39-amino acid linear peptide and a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is conjugated to a C20 fatty diacid moiety via a linker, which enhances albumin binding and extends its metabolic stability in laboratory models.

This compound is intended for in vitro and in vivo laboratory research only, specifically for the study of dual-receptor signaling and metabolic pathways.

Research Applications

• Dual-Agonist Signaling: Investigation into the synergistic effects of dual-receptor signaling within the incretin system.
• Incretin Mimetic Analysis: Investigating the role of synthetic polypeptides in gastric emptying and insulin secretion in animal models.
• Binding Affinity Research: Exploring the impact of the C20 fatty diacid moiety on plasma protein binding and pharmacokinetic profiles.
• Metabolic Proteomics: Analysis of proteolytic cleavage patterns and beta-oxidation of fatty acid chains in synthetic peptides.

SOLD FOR RESEARCH PURPOSES ONLY

• Not for human consumption. Research Only.
• Storage: Keep lyophilized powder cool/dry. Refrigerate after reconstitution.
• BAC Water Sold Separately
• Syringes Not Included
• Peptides Sold in Powdered Form